Travere director awarded stock and options

Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 05/21/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.

Travere Therapeutics director Roy D. Baynes received new equity compensation awards. He was granted 4,000 shares of common stock at no cost and a stock option covering 12,000 shares with a strike price of $42.26 per share.

The awards were made as an automatic equity grant under Travere’s 2018 Equity Incentive Plan pursuant to the non-employee director compensation program. The equity award vests over one year, and following the stock grant Baynes directly holds 41,500 shares of common stock.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 2 txns

Insider Baynes Roy D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	12,000	$0.00	$0.00
Grant/Award	Common Stock	4,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 12,000 options (Direct); Common Stock — 41,500 shares (Direct)

Holdings Before and After: Stock option (right to buy), 0 to 12,000 options (Direct); Common Stock, 37,500 to 41,500 shares (Direct)

Footnotes (2)

1. F1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
2. F2. The equity award vests over a one year period.

Key Figures

Stock grant: 4,000 shares Option grant size: 12,000 shares Option exercise price: $42.26 per share +3 more

6 metrics

Stock grant 4,000 shares Common stock awarded on May 19, 2026

Option grant size 12,000 shares Stock option (right to buy) granted May 19, 2026

Option exercise price $42.26 per share Conversion/exercise price for stock option

Shares after grant 41,500 shares Common shares directly held following stock grant

Option exercisability date May 19, 2027 Exercise date for the stock option

Option expiration May 19, 2036 Expiration date for the stock option

Key Terms

Automatic equity grant, 2018 Equity Incentive Plan, non-employee director compensation program, Stock option (right to buy)

4 terms

Automatic equity grant financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan"

2018 Equity Incentive Plan financial

"under the Issuer's 2018 Equity Incentive Plan, as amended"

non-employee director compensation program financial

"pursuant to the non-employee director compensation program"

Stock option (right to buy) financial

"Stock option (right to buy) reported as a derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Travere Therapeutics (TVTX) director Roy D. Baynes report on this Form 4?

Roy D. Baynes reported receiving equity compensation, not buying shares on the market. He was granted 4,000 Travere Therapeutics common shares and a stock option over 12,000 shares as part of the non-employee director compensation program.

How many Travere Therapeutics (TVTX) shares were granted to Roy D. Baynes?

Roy D. Baynes was granted 4,000 shares of Travere Therapeutics common stock. These shares were awarded at a price of $0.00 per share as an automatic equity grant under the company’s 2018 Equity Incentive Plan for non-employee directors.

What stock options did Roy D. Baynes receive from Travere Therapeutics (TVTX)?

Baynes received a stock option for 12,000 Travere Therapeutics shares. The option has an exercise price of $42.26 per share, becomes exercisable starting on May 19, 2027, and is scheduled to expire on May 19, 2036, subject to plan terms.

Is the Travere Therapeutics (TVTX) Form 4 a market purchase or a compensation grant?

The Form 4 reflects compensation grants, not open-market purchases. Both the 4,000-share stock award and 12,000-share stock option were automatic equity grants under Travere’s 2018 Equity Incentive Plan for non-employee directors, with no cash price paid per share at grant.

How many Travere Therapeutics (TVTX) shares does Roy D. Baynes hold after these awards?

After the 4,000-share stock grant, Baynes directly holds 41,500 Travere Therapeutics common shares. This total reflects his direct ownership position reported in the filing and excludes the 12,000 underlying shares covered by the newly granted stock option.

How do the Travere Therapeutics (TVTX) director equity awards vest?

The equity award reported for Roy D. Baynes vests over one year. This means the granted stock and associated compensation are earned across a one-year period, consistent with the non-employee director compensation program under Travere’s 2018 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baynes Roy D.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		4,000(1)(2)	A	$0	41,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$42.26	05/19/2026		A		12,000(1)		05/19/2027(2)	05/19/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

2. The equity award vests over a one year period.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)